Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

This is a long-term study in cystic fibrosis patients who are participating in the Cystic
Fibrosis Patient Registry to assess the occurrence and risk factors for a rare bowel
disorder called fibrosing colonopathy (narrowing of the large intestine). Patients will be
followed at their regular clinical care visits over a 10-year period and approached if they
develop symptoms of fibrosing colonopathy for collection and use of further detailed
information.

Eligibility Criteria

Inclusion Criteria:

The inclusion criteria for enrollment in the Base Study Population

- Diagnosed with cystic fibrosis,

- Enrolled in the Cystic Fibrosis Patient Registry

- Receiving medical care at a Cystic Fibrosis Foundation-accredited care center
providing data to the Cystic Fibrosis Patient Registry

 

Principal Investigator

Gerhard J Leitz

Study Contact

Christopher Dowd, cdowd@cff.org, 301-841-2606

Estimated Completion Date

Sunday, July 31, 2022

ClinicalTrials.gov #

NCT01652157
04/17/2017